Last reviewed · How we verify
NCT06914869
Drug-Drug Interaction Potential of Mavorixafor
Phase 1 trial testing Mavorixafor in Healthy Participants in 38 participants. Completed in 19 May 2025.
19 May 2025
Quick facts
| Lead sponsor | X4 Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 38 |
| Start date | 18 February 2025 |
| Primary completion | 19 May 2025 |
| Estimated completion | 19 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Mavorixafor (MAVORIXAFOR) — full drug profile →
- Carbamazepine (carbamazepine) — full drug profile →
- Efavirenz (EFAVIRENZ) — full drug profile →
Conditions studied
- Healthy Participants — all drugs for Healthy Participants →
Sponsor
X4 Pharmaceuticals — full company profile →
Who can join
Adults 18 to 55, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06914869
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mavorixafor
Trials testing the same drug.
- NCT04154488 — A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders · Phase 1, PHASE2 · completed
- NCT04274738 — A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tum · Phase 1 · completed
Other recruiting trials for Healthy Participants
Currently open trials in the same condition.
- NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
- NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
- NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
- NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
- NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
Other X4 Pharmaceuticals trials
Trials by the same sponsor.
- NCT04154488 — A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders · Phase 1, PHASE2 · completed
- NCT04274738 — A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tum · Phase 1 · completed
- NCT02923531 — Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma · Phase 1, PHASE2 · terminated
- NCT02823405 — X4P-001 and Pembrolizumab in Patients With Advanced Melanoma · Phase 1 · completed
- NCT02667886 — Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06914869 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by X4 Pharmaceuticals
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06914869.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing